Page last updated: 2024-08-23

tridemorph and lapatinib

tridemorph has been researched along with lapatinib in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Flores, LM; Hemler, ME; Krop, IE; Li, Q; Xu, F; Yang, XH; Zhou, P	1

Other Studies

1 other study(ies) available for tridemorph and lapatinib

Article	Year
Disruption of laminin-integrin-CD151-focal adhesion kinase axis sensitizes breast cancer cells to ErbB2 antagonists. Cancer research, 2010, Mar-15, Volume: 70, Issue:6 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antigens, CD; Antineoplastic Agents; Breast Neoplasms; Cell Adhesion Molecules; Cell Line, Tumor; Drug Synergism; Enzyme Activation; Focal Adhesion Protein-Tyrosine Kinases; Humans; Integrin alpha3beta1; Integrin alpha6beta4; Kalinin; Lapatinib; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Signal Transduction; Tetraspanin 24; Trastuzumab	2010

Article

Year

Disruption of laminin-integrin-CD151-focal adhesion kinase axis sensitizes breast cancer cells to ErbB2 antagonists.

Cancer research, 2010, Mar-15, Volume: 70, Issue:6

Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antigens, CD; Antineoplastic Agents; Breast Neoplasms; Cell Adhesion Molecules; Cell Line, Tumor; Drug Synergism; Enzyme Activation; Focal Adhesion Protein-Tyrosine Kinases; Humans; Integrin alpha3beta1; Integrin alpha6beta4; Kalinin; Lapatinib; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Signal Transduction; Tetraspanin 24; Trastuzumab

2010